CAPITAL Chemist Group is aiming to boost medication adherence with its new medicine service (NMS).
The Capital Chemist NMS was launched at the group's Forum 17 over the weekend, to support patients with complex or chronic health conditions when starting a new medication.
The service will also double as a minor ailments service, allowing pharmacists to record their recommendations in a format that can be given to patients.
Capital Chemist Group Business Manager, Andrew Topp, said discussions with patients will take place in a private consultation area, and should take approximately 10 minutes.
"Our pharmacists have been asking for new tools to support patients with their medications," he said.
"Modelled on the UK National Health Service NMS, the program aims to empower patients with factual useful information on dosages, timing, side effects, actions to take if there are side effects, duration of therapy and more.
"While a CMI might provide much of this information, a CMI cannot take into account patient indivdual needs and preferences; we feel strongly that this will help us to optimise treatment outcomes for our patients."
Topp noted that evidence from the UK had shown that the NMS had increased medication adherence compared with normal practice, delivering improved outcomes and reducing patient costs.
The above article was sent to subscribers in Pharmacy Daily's issue from 18 Oct 22
To see the full newsletter, see the embedded issue below or CLICK HERE to download Pharmacy Daily from 18 Oct 22
